SCHEMBL10160835

SCHEMBL10160835

COc1c(C(=O)Oc2ccccc2)c(C)cc2c(Br)cccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.41
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40
TUBB3 Q13509 1/20 0.40
TUBB2A Q13885 1/20 0.40
TUBB8 Q3ZCM7 1/20 0.40
TUBA3E Q6PEY2 1/20 0.40
TUBA1A Q71U36 1/20 0.40
TUBA1C Q9BQE3 1/20 0.40
TUBB6 Q9BUF5 1/20 0.40
TUBB2B Q9BVA1 1/20 0.40
TUBB1 Q9H4B7 1/20 0.40
MAPT P10636 7/20 0.40
RAB9A P51151 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
HTR1A P08908 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10160847 0.85 CA12 (0.41) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL10161340 0.85 THRA (0.42) MAPTTP53HPGDTDP1ALDH1A1
SCHEMBL10160837 0.84 ELANE (0.36) L3MBTL1MAPTRAB9ANPSR1NPC1
SCHEMBL10196582 0.84 THRA (0.40) L3MBTL1MAPTKMT2AMEN1LMNA
SCHEMBL10160471 0.79 MAPT (0.42) L3MBTL1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL10161344 0.75 MAPT (0.51) MAPTKMT2ATP53MEN1HPGD
SCHEMBL10161339 0.75 MRGPRX4 (0.46) L3MBTL1MAPTKMT2ATP53MEN1
SCHEMBL10196117 0.74 MEN1 (0.43) L3MBTL1MAPTPOLBKMT2ATP53
SCHEMBL10161353 0.74 POLB (0.38) L3MBTL1MAPTRAB9ANPSR1HTR1A
SCHEMBL15521372 0.73 MAPT (0.47) MAPTRAB9ANPSR1NPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115819-A1 Pentacycline Compounds TETRAPHASE PHARMACEUTICALS, INC. 2012-05-10 US disclosed
US-20120115819-A1 Pentacycline Compounds TETRAPHASE PHARMACEUTICALS, INC. 2012-05-10 US disclosed
WO-2010132670-A2 PENTACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS, INC. (US) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115819-A1 Pentacycline Compounds TSLP, IL5, IL17A L3MBTL1 4505/4885TUBB4A 46/4885TUBB 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.